Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 55 entries
Sorted by: Best Match Show Resources per page
The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy".

PharmacoEconomics

Grutters JP, van Asselt MB, Chalkidou K, Joore MA.
PMID: 26314283
Pharmacoeconomics. 2015 Sep;33(9):983. doi: 10.1007/s40273-015-0321-8.

No abstract available.

Cite
Grutters JP, van Asselt MB, Chalkidou K, et al. The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy". Pharmacoeconomics. 2015;33(9):983doi: 10.1007/s40273-015-0321-8.
Grutters, J. P., van Asselt, M. B., Chalkidou, K., & Joore, M. A. (2015). The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy". PharmacoEconomics, 33(9), 983. https://doi.org/10.1007/s40273-015-0321-8
Grutters, Janneke P C, et al. "The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy"." PharmacoEconomics vol. 33,9 (2015): 983. doi: https://doi.org/10.1007/s40273-015-0321-8
Grutters JP, van Asselt MB, Chalkidou K, Joore MA. The Authors' Reply: Comment on "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy". Pharmacoeconomics. 2015 Sep;33(9):983. doi: 10.1007/s40273-015-0321-8. PMID: 26314283.
Copy Download .nbib Format: NLM
Is competition bad for our health(care)? We simply don't know.

The Lancet. Oncology

Chalkidou K.
PMID: 28986013
Lancet Oncol. 2017 Nov;18(11):1424-1425. doi: 10.1016/S1470-2045(17)30623-X. Epub 2017 Oct 03.

No abstract available.

Cite
Chalkidou K. Is competition bad for our health(care)? We simply don't know. Lancet Oncol. 2017;18(11):1424-1425doi: 10.1016/S1470-2045(17)30623-X.
Chalkidou, K. (2017). Is competition bad for our health(care)? We simply don't know. The Lancet. Oncology, 18(11), 1424-1425. https://doi.org/10.1016/S1470-2045(17)30623-X
Chalkidou, Kalipso. "Is competition bad for our health(care)? We simply don't know." The Lancet. Oncology vol. 18,11 (2017): 1424-1425. doi: https://doi.org/10.1016/S1470-2045(17)30623-X
Chalkidou K. Is competition bad for our health(care)? We simply don't know. Lancet Oncol. 2017 Nov;18(11):1424-1425. doi: 10.1016/S1470-2045(17)30623-X. Epub 2017 Oct 03. PMID: 28986013.
Copy Download .nbib Format: NLM
Management of a Solitary Bone Metastasis to the Tibia from Colorectal Cancer.

Case reports in gastroenterology

Chalkidou AS, Boutis AL, Padelis P.
PMID: 21103253
Case Rep Gastroenterol. 2009 Nov 21;3(3):354-359. doi: 10.1159/000239626.

The onset of osseous metastases during the course of colorectal cancer is not common. When they appear they are usually combined with visceral metastases to the liver, lungs and brain. In our report we refer to the case of...

Cite
Chalkidou AS, Boutis AL, Padelis P. Management of a Solitary Bone Metastasis to the Tibia from Colorectal Cancer. Case Rep Gastroenterol. 2009;3(3):354-359doi: 10.1159/000239626.
Chalkidou, A. S., Boutis, A. L., & Padelis, P. (2009). Management of a Solitary Bone Metastasis to the Tibia from Colorectal Cancer. Case reports in gastroenterology, 3(3), 354-359. https://doi.org/10.1159/000239626
Chalkidou, Anastasia S, et al. "Management of a Solitary Bone Metastasis to the Tibia from Colorectal Cancer." Case reports in gastroenterology vol. 3,3 (2009): 354-359. doi: https://doi.org/10.1159/000239626
Chalkidou AS, Boutis AL, Padelis P. Management of a Solitary Bone Metastasis to the Tibia from Colorectal Cancer. Case Rep Gastroenterol. 2009 Nov 21;3(3):354-359. doi: 10.1159/000239626. PMID: 21103253; PMCID: PMC2988929.
Copy Download .nbib Format: NLM
Correction to: The Future of Precision Medicine: Potential Impacts for Health Technology Assessment.

PharmacoEconomics

Love-Koh J, Peel A, Rejon-Parrilla JC, Ennis K, Lovett R, Manca A, Chalkidou A, Wood H, Taylor M.
PMID: 30361887
Pharmacoeconomics. 2019 Jan;37(1):117. doi: 10.1007/s40273-018-0739-x.

The article The Future of Precision Medicine: Potential Impacts for Health Technology Assessment written by James Love‑Koh, Alison Peel Juan, Carlos Rejon‑Parrilla, KateAnastasia Chalkidou, Hannah Wood, Matthew Taylor was originally published electronically on the publisher's internet portal (currently Springer...

Cite
Love-Koh J, Peel A, Rejon-Parrilla JC, et al. Correction to: The Future of Precision Medicine: Potential Impacts for Health Technology Assessment. Pharmacoeconomics. 2019;37(1):117doi: 10.1007/s40273-018-0739-x.
Love-Koh, J., Peel, A., Rejon-Parrilla, J. C., Ennis, K., Lovett, R., Manca, A., Chalkidou, A., Wood, H., & Taylor, M. (2019). Correction to: The Future of Precision Medicine: Potential Impacts for Health Technology Assessment. PharmacoEconomics, 37(1), 117. https://doi.org/10.1007/s40273-018-0739-x
Love-Koh, James, et al. "Correction to: The Future of Precision Medicine: Potential Impacts for Health Technology Assessment." PharmacoEconomics vol. 37,1 (2019): 117. doi: https://doi.org/10.1007/s40273-018-0739-x
Love-Koh J, Peel A, Rejon-Parrilla JC, Ennis K, Lovett R, Manca A, Chalkidou A, Wood H, Taylor M. Correction to: The Future of Precision Medicine: Potential Impacts for Health Technology Assessment. Pharmacoeconomics. 2019 Jan;37(1):117. doi: 10.1007/s40273-018-0739-x. PMID: 30361887; PMCID: PMC6830397.
Copy Download .nbib Format: NLM
High US Health-Care Spending and the Importance of Provider Payment Rates.

Forum for health economics & policy

Anderson G, Chalkidou K, Herring B.
PMID: 31419860
Forum Health Econ Policy. 2012 Sep 10;15(3):1-22. doi: 10.1515/fhep-2012-0007.

We compare health care spending in the USA to other industrialized countries and find that payment rates for hospitals, physicians, and drugs are generally much higher in the USA than they are in other industrialized countries while the quantity...

Cite
Anderson G, Chalkidou K, Herring B. High US Health-Care Spending and the Importance of Provider Payment Rates. Forum Health Econ Policy. 2012;15(3):1-22doi: 10.1515/fhep-2012-0007.
Anderson, G., Chalkidou, K., & Herring, B. (2012). High US Health-Care Spending and the Importance of Provider Payment Rates. Forum for health economics & policy, 15(3), 1-22. https://doi.org/10.1515/fhep-2012-0007
Anderson, Gerard, et al. "High US Health-Care Spending and the Importance of Provider Payment Rates." Forum for health economics & policy vol. 15,3 (2012): 1-22. doi: https://doi.org/10.1515/fhep-2012-0007
Anderson G, Chalkidou K, Herring B. High US Health-Care Spending and the Importance of Provider Payment Rates. Forum Health Econ Policy. 2012 Sep 10;15(3):1-22. doi: 10.1515/fhep-2012-0007. PMID: 31419860.
Copy Download .nbib Format: NLM
Evidence-informed capacity building for setting health priorities in low- and middle-income countries: A framework and recommendations for further research.

F1000Research

Li R, Ruiz F, Culyer AJ, Chalkidou K, Hofman KJ.
PMID: 28721199
F1000Res. 2017 Mar 07;6:231. doi: 10.12688/f1000research.10966.1. eCollection 2017.

Priority-setting in health is risky and challenging, particularly in resource-constrained settings. It is not simply a narrow technical exercise, and involves the mobilisation of a wide range of capacities among stakeholders - not only the technical capacity to "do"...

Cite
Li R, Ruiz F, Culyer AJ, et al. Evidence-informed capacity building for setting health priorities in low- and middle-income countries: A framework and recommendations for further research. F1000Res. 2017;6:231doi: 10.12688/f1000research.10966.1.
Li, R., Ruiz, F., Culyer, A. J., Chalkidou, K., & Hofman, K. J. (2017). Evidence-informed capacity building for setting health priorities in low- and middle-income countries: A framework and recommendations for further research. F1000Research, 6231. https://doi.org/10.12688/f1000research.10966.1
Li, Ryan, et al. "Evidence-informed capacity building for setting health priorities in low- and middle-income countries: A framework and recommendations for further research." F1000Research vol. 6 (2017): 231. doi: https://doi.org/10.12688/f1000research.10966.1
Li R, Ruiz F, Culyer AJ, Chalkidou K, Hofman KJ. Evidence-informed capacity building for setting health priorities in low- and middle-income countries: A framework and recommendations for further research. F1000Res. 2017 Mar 07;6:231. doi: 10.12688/f1000research.10966.1. eCollection 2017. PMID: 28721199; PMCID: PMC5497935.
Copy Download .nbib Format: NLM
Identification of publicly available data sources to inform the conduct of Health Technology Assessment in India.

F1000Research

Downey L, Rao N, Guinness L, Asaria M, Prinja S, Sinha A, Kant R, Pandey A, Cluzeau F, Chalkidou K.
PMID: 29770210
F1000Res. 2018 Feb 28;7:245. doi: 10.12688/f1000research.14041.2. eCollection 2018.

No abstract available.

Cite
Downey L, Rao N, Guinness L, et al. Identification of publicly available data sources to inform the conduct of Health Technology Assessment in India. F1000Res. 2018;7:245doi: 10.12688/f1000research.14041.2.
Downey, L., Rao, N., Guinness, L., Asaria, M., Prinja, S., Sinha, A., Kant, R., Pandey, A., Cluzeau, F., & Chalkidou, K. (2018). Identification of publicly available data sources to inform the conduct of Health Technology Assessment in India. F1000Research, 7245. https://doi.org/10.12688/f1000research.14041.2
Downey, Laura, et al. "Identification of publicly available data sources to inform the conduct of Health Technology Assessment in India." F1000Research vol. 7 (2018): 245. doi: https://doi.org/10.12688/f1000research.14041.2
Downey L, Rao N, Guinness L, Asaria M, Prinja S, Sinha A, Kant R, Pandey A, Cluzeau F, Chalkidou K. Identification of publicly available data sources to inform the conduct of Health Technology Assessment in India. F1000Res. 2018 Feb 28;7:245. doi: 10.12688/f1000research.14041.2. eCollection 2018. PMID: 29770210; PMCID: PMC5930391.
Copy Download .nbib Format: NLM
Improving the quality of economic evaluation in health in low- and middle-income countries: where are we now?.

Journal of comparative effectiveness research

Wilkinson T, Chalkidou K.
PMID: 31558038
J Comp Eff Res. 2019 Oct;8(13):1041-1043. doi: 10.2217/cer-2019-0119. Epub 2019 Sep 27.

No abstract available.

Cite
Wilkinson T, Chalkidou K. Improving the quality of economic evaluation in health in low- and middle-income countries: where are we now?. J Comp Eff Res. 2019;8(13):1041-1043doi: 10.2217/cer-2019-0119.
Wilkinson, T., & Chalkidou, K. (2019). Improving the quality of economic evaluation in health in low- and middle-income countries: where are we now?. Journal of comparative effectiveness research, 8(13), 1041-1043. https://doi.org/10.2217/cer-2019-0119
Wilkinson, Thomas, and Chalkidou, Kalipso. "Improving the quality of economic evaluation in health in low- and middle-income countries: where are we now?." Journal of comparative effectiveness research vol. 8,13 (2019): 1041-1043. doi: https://doi.org/10.2217/cer-2019-0119
Wilkinson T, Chalkidou K. Improving the quality of economic evaluation in health in low- and middle-income countries: where are we now?. J Comp Eff Res. 2019 Oct;8(13):1041-1043. doi: 10.2217/cer-2019-0119. Epub 2019 Sep 27. PMID: 31558038.
Copy Download .nbib Format: NLM
Neonatal Birth Weight of the Woman as a Risk Factor for Breast Cancer in her Life: a Case-Control Bicentric Study.

Materia socio-medica

Bothou A, Zervoudis S, Tsatsaris G, Pappou P, Liadopoulou M, Iatrakis G, Gerende A, Chalkidou A, Nikolettos N, Tsikouras P.
PMID: 34483740
Mater Sociomed. 2021 Jun;33(2):119-123. doi: 10.5455/msm.2021.33.119-123.

BACKGROUND: It is a global fact that the birth weight is increasing during the years around the world and for this reason it is very important to be examined as a potential risk factor for breast cancer. According to...

Cite
Bothou A, Zervoudis S, Tsatsaris G, et al. Neonatal Birth Weight of the Woman as a Risk Factor for Breast Cancer in her Life: a Case-Control Bicentric Study. Mater Sociomed. 2021;33(2):119-123doi: 10.5455/msm.2021.33.119-123.
Bothou, A., Zervoudis, S., Tsatsaris, G., Pappou, P., Liadopoulou, M., Iatrakis, G., Gerende, A., Chalkidou, A., Nikolettos, N., & Tsikouras, P. (2021). Neonatal Birth Weight of the Woman as a Risk Factor for Breast Cancer in her Life: a Case-Control Bicentric Study. Materia socio-medica, 33(2), 119-123. https://doi.org/10.5455/msm.2021.33.119-123
Bothou, Anastasia, et al. "Neonatal Birth Weight of the Woman as a Risk Factor for Breast Cancer in her Life: a Case-Control Bicentric Study." Materia socio-medica vol. 33,2 (2021): 119-123. doi: https://doi.org/10.5455/msm.2021.33.119-123
Bothou A, Zervoudis S, Tsatsaris G, Pappou P, Liadopoulou M, Iatrakis G, Gerende A, Chalkidou A, Nikolettos N, Tsikouras P. Neonatal Birth Weight of the Woman as a Risk Factor for Breast Cancer in her Life: a Case-Control Bicentric Study. Mater Sociomed. 2021 Jun;33(2):119-123. doi: 10.5455/msm.2021.33.119-123. PMID: 34483740; PMCID: PMC8385737.
Copy Download .nbib Format: NLM
Significance of changes in inflammatory parameters following uterine artery embolization in pre-menopausal females.

Experimental and therapeutic medicine

Souftas V, Deuteraiou D, Anthoulaki X, Chalkidou A, Bothou A, Gaidatzi F, Tsypsianis G, Iatrakis G, Zervoudis S, Souftas D, Michalopoulos S, Vogiatzaki T, Galazios G, Nikolettos N, Tsikouras P.
PMID: 32346432
Exp Ther Med. 2020 Jun;19(6):3684-3690. doi: 10.3892/etm.2020.8652. Epub 2020 Apr 09.

The purpose of the present study was to describe the course of changes in laboratory inflammatory markers following bilateral uterine artery embolization (UAE) as a treatment for leiomyomas and adenomyosis. The body temperature was measured and blood samples were...

Cite
Souftas V, Deuteraiou D, Anthoulaki X, et al. Significance of changes in inflammatory parameters following uterine artery embolization in pre-menopausal females. Exp Ther Med. 2020;19(6):3684-3690doi: 10.3892/etm.2020.8652.
Souftas, V., Deuteraiou, D., Anthoulaki, X., Chalkidou, A., Bothou, A., Gaidatzi, F., Tsypsianis, G., Iatrakis, G., Zervoudis, S., Souftas, D., Michalopoulos, S., Vogiatzaki, T., Galazios, G., Nikolettos, N., & Tsikouras, P. (2020). Significance of changes in inflammatory parameters following uterine artery embolization in pre-menopausal females. Experimental and therapeutic medicine, 19(6), 3684-3690. https://doi.org/10.3892/etm.2020.8652
Souftas, Vasileios, et al. "Significance of changes in inflammatory parameters following uterine artery embolization in pre-menopausal females." Experimental and therapeutic medicine vol. 19,6 (2020): 3684-3690. doi: https://doi.org/10.3892/etm.2020.8652
Souftas V, Deuteraiou D, Anthoulaki X, Chalkidou A, Bothou A, Gaidatzi F, Tsypsianis G, Iatrakis G, Zervoudis S, Souftas D, Michalopoulos S, Vogiatzaki T, Galazios G, Nikolettos N, Tsikouras P. Significance of changes in inflammatory parameters following uterine artery embolization in pre-menopausal females. Exp Ther Med. 2020 Jun;19(6):3684-3690. doi: 10.3892/etm.2020.8652. Epub 2020 Apr 09. PMID: 32346432; PMCID: PMC7185183.
Copy Download .nbib Format: NLM
Valuing Protection against Health-Related Financial Risks.

Journal of benefit-cost analysis

Skinner J, Chalkidou K, Jamison DT.
PMID: 32844080
J Benefit Cost Anal. 2019;10:106-131. doi: 10.1017/bca.2018.30. Epub 2019 Feb 08.

There is strong interest in both developing and developed countries towards expanding health insurance coverage. How should the benefits, and costs, of expanded coverage be measured? While the value of reducing the financial risks that result from insurance coverage...

Cite
Skinner J, Chalkidou K, Jamison DT. Valuing Protection against Health-Related Financial Risks. J Benefit Cost Anal. 2019;10:106-131doi: 10.1017/bca.2018.30.
Skinner, J., Chalkidou, K., & Jamison, D. T. (2019). Valuing Protection against Health-Related Financial Risks. Journal of benefit-cost analysis, 10106-131. https://doi.org/10.1017/bca.2018.30
Skinner, Jonathan, et al. "Valuing Protection against Health-Related Financial Risks." Journal of benefit-cost analysis vol. 10 (2019): 106-131. doi: https://doi.org/10.1017/bca.2018.30
Skinner J, Chalkidou K, Jamison DT. Valuing Protection against Health-Related Financial Risks. J Benefit Cost Anal. 2019;10:106-131. doi: 10.1017/bca.2018.30. Epub 2019 Feb 08. PMID: 32844080; PMCID: PMC7444749.
Copy Download .nbib Format: NLM
Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Colson AR, Morton A, Årdal C, Chalkidou K, Davies SC, Garrison LP, Jit M, Laxminarayan R, Megiddo I, Morel C, Nonvignon J, Outterson K, Rex JH, Sarker AR, Sculpher M, Woods B, Xiao Y.
PMID: 34838281
Value Health. 2021 Dec;24(12):1828-1834. doi: 10.1016/j.jval.2021.06.002. Epub 2021 Sep 20.

Antimicrobial resistance is a serious challenge to the success and sustainability of our healthcare systems. There has been increasing policy attention given to antimicrobial resistance in the last few years, and increased amounts of funding have been channeled into...

Cite
Colson AR, Morton A, Årdal C, et al. Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?. Value Health. 2021;24(12):1828-1834doi: 10.1016/j.jval.2021.06.002.
Colson, A. R., Morton, A., Årdal, C., Chalkidou, K., Davies, S. C., Garrison, L. P., Jit, M., Laxminarayan, R., Megiddo, I., Morel, C., Nonvignon, J., Outterson, K., Rex, J. H., Sarker, A. R., Sculpher, M., Woods, B., & Xiao, Y. (2021). Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(12), 1828-1834. https://doi.org/10.1016/j.jval.2021.06.002
Colson, Abigail R, et al. "Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 24,12 (2021): 1828-1834. doi: https://doi.org/10.1016/j.jval.2021.06.002
Colson AR, Morton A, Årdal C, Chalkidou K, Davies SC, Garrison LP, Jit M, Laxminarayan R, Megiddo I, Morel C, Nonvignon J, Outterson K, Rex JH, Sarker AR, Sculpher M, Woods B, Xiao Y. Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?. Value Health. 2021 Dec;24(12):1828-1834. doi: 10.1016/j.jval.2021.06.002. Epub 2021 Sep 20. PMID: 34838281.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 55 entries